fbpx
Saturday, January 16, 2021
Alzheimer’s drug that stopped working early tests now called efficient, heads to FDA

Alzheimer’s drug that stopped working early tests now called efficient, heads...

0
Enlarge / The exterior of the headquarters of biotechnology company Biogen in Cambridge, Massachusetts. An experimental treatment for Alzheimer's disease is headed to the Food and Drug Administration for approval—despite the fact that it flunked a "futility analysis" and was abandoned by its maker just months ago. In March, biotech company Biogen halted two Phase…

Recent Posts